There was a big asterisk with the company's improved bottom line.Exact Sciences(NASDAQ: EXAS) hasn't delivered the sizzling performance so far in 2021 that it did last year. That hasn't stopped Cathie Wood from scooping up more shares of the molecular diagnostics company for her ARK Innovation ETF (...

https://www.fool.com/investing/2021/05/05/exact-sciences-beat-expectations-in-q1-why-investo/?source=iedfolrf0000001

#fool